Castle Biosciences Reports First Quarter 2024 Results

Q1 2024 revenue increased 74% over Q1 2023 to $73 million


Q1 2024 total test reports increased 40% over Q1 2023


Raising full-year 2024 revenue guidance to $255-265 million from $235-240...

Related Keywords

United States ,Israel ,Russia ,Ukraine ,American ,Castle Biosciences ,Derek Maetzold ,Program Registries ,Mental Health ,See The Company ,Instagram ,Securities Exchange ,Facebook ,Castle Biosciences Inc ,National Cancer Institute Surveillance ,Linkedin ,Nasdaq ,National Comprehensive Cancer Network ,American Joint Committee On Cancer Staging Manual ,Medicare Contractors ,Decisiondx Melanoma Class ,Quarter Ended March ,Path Melanoma ,Adjusted Gross Margin ,Cash Equivalents ,Marketable Investment ,Recent Accomplishments ,American Joint Committee ,Cancer Staging Manual ,National Cancer Institute ,End Results ,Investor Relations ,Adjusted Revenues ,Gross Margin ,Adjusted Gross ,Mypath Melanoma ,Securities Act ,Securities Exchange Act ,Israel Hamas War ,Tissuecypher Test ,Annual Report ,Quarterly Report ,Markets ,